Zacks Research Has Bullish Estimate for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at Zacks Research boosted their FY2026 earnings estimates for shares of Protalix BioTherapeutics in a research report issued on Wednesday, March 18th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings per share of $0.17 for the year, up from their prior estimate of ($0.06). The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ FY2027 earnings at $0.00 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Protalix BioTherapeutics in a research note on Thursday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.00.

Protalix BioTherapeutics Stock Performance

NYSE:PLX opened at $2.14 on Monday. The stock has a market capitalization of $172.42 million, a PE ratio of -16.46 and a beta of -0.26. Protalix BioTherapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $3.19. The company has a fifty day moving average of $2.61 and a two-hundred day moving average of $2.21.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Protalix BioTherapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 830,054 shares of the company’s stock valued at $1,494,000 after purchasing an additional 10,277 shares in the last quarter. State Street Corp grew its holdings in shares of Protalix BioTherapeutics by 17.4% during the fourth quarter. State Street Corp now owns 585,261 shares of the company’s stock worth $1,053,000 after buying an additional 86,714 shares in the last quarter. Stratos Wealth Partners LTD. raised its position in shares of Protalix BioTherapeutics by 42.9% in the third quarter. Stratos Wealth Partners LTD. now owns 500,000 shares of the company’s stock valued at $1,110,000 after buying an additional 150,000 shares during the last quarter. Jane Street Group LLC raised its position in shares of Protalix BioTherapeutics by 159.0% in the first quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock valued at $753,000 after buying an additional 180,702 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Protalix BioTherapeutics by 482.3% in the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock worth $741,000 after buying an additional 239,751 shares in the last quarter. 16.53% of the stock is owned by institutional investors and hedge funds.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.